Company: SINT
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021930
Chunk: 29

Company: Sintx Technologies, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 29
---
 in operations. Our continuation as a going concern is dependent upon its ability to increase sales, decrease
expenses and raise additional funding. It is uncertain when, if ever, we will attain profitability and positive cash flows from operations
or obtain additional financing.

We
continue to seek opportunities to raise additional funding through equity and/or debt financing. However, such funding is not guaranteed
and may not be available on favorable terms and may involve restrictive covenants. Any additional equity financing, if
available, will most likely be dilutive to its current stockholders. If we are not able to obtain additional debt
or equity financing, the impact on our company and business will be material and adverse.

The
board of directors, together with management, remains focused on advancing our business strategy and focus. Our
strategic emphasis is focused on utilizing our technology in making advancements in the biomedical sector. Historically engaged in both
industrial and biomedical applications, we have prioritized the development and commercialization of innovative medical devices, leveraging
its expertise in advanced ceramics and biomaterials. This renewed focus aligns with a commitment to improving patient outcomes through
the creation of products designed for surgical, orthopedic, and other specialized medical applications. We are concentrating our resources
on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon nitride—provide
a distinct competitive advantage due to their unique strength, durability, and biocompatibility.

20

Through
this transformation, as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC® Foot & Ankle Osteotomy Wedge
System, our aim is to deliver meaningful innovations to the medical community. Our current research and development pipeline is
centered on medical-grade devices that incorporate antimicrobial properties, enhanced imaging capabilities, and durability under
physiological conditions, which are critical for orthopedic implants, spinal fusion devices, and other surgical tools. As we
transition our focus away from industrial applications, we anticipate this strategic shift will enable us to better serve the
medical sector, address critical unmet needs, and position SINTX as a leading provider in the medical device market. By focusing on
partnerships and collaborations with healthcare institutions and industry leaders, we believe that we are positioned to expand our
footprint in the medical device sector and drive shareholder value through sustainable, high-impact innovations.

On
August 8, 2024, the board of directors approved a plan to implement a Company-wide reduction in the workforce